<DOC>
	<DOCNO>NCT01313429</DOCNO>
	<brief_summary>Background : - Certain type cancer , include sarcoma melanoma , specific antigen ( protein molecule ) surface . Research show produce immune reaction antigen may able keep tumor grow encourage immune system destroy tumor cell . By create vaccine contains antigens similar find cancer cell , researcher hope cause immune reaction target cancer cell . However , research need determine safety effectiveness type vaccine treatment . Objectives : - To determine whether tumor cell vaccine , give individual surgery remove malignant tumor chest , cause immune reaction prevent tumor come back . Eligibility : - Individuals least 18 year age diagnose cancer spread lung , pleura , mediastinum , recently surgery remove tumor chest . Design : - Participants screen physical examination medical history , well blood test image study . - Participants option leukapheresis collect white blood cell study body respond vaccine . Participants agree procedure start treatment sixth eighth vaccine . - Seven day first vaccine , participant receive chemotherapy drug celecoxib cyclophosphamide take twice day home . - Participants receive experimental vaccine injection thigh arm , may receive two shot depend many cell vaccine . Participants receive diary monitor medication dose side effect , well additional cyclophosphamide celecoxib take home direct study . - Participants one vaccine every month 6 month , regular blood test image study . After sixth vaccine , participant successfully respond treatment two additional vaccine give 3 month apart . - After eighth vaccine , participant followup visit every 3 month 1 year every 6 month 4 year ... .</brief_summary>
	<brief_title>Tumor Cell Vaccine Patients Undergoing Surgery Sarcomas , Melanomas , Germ Cell Tumors , Malignancies That Have Metastasized Lungs , Pleura , Mediastinum</brief_title>
	<detailed_description>Background : During recent year , cancer-testis ( CT ) antigens ( CTA ) emerge attractive target cancer immunotherapy . Whereas malignancies diverse histology express variety CTAs , immune response antigens appear uncommon cancer patient , possibly due low-level , heterogeneous antigen expression , well immunosuppressive regulatory T cell . Conceivably , vaccination cancer patient allogeneic tumor cell express high level multiple CTAs combination depletion T regulatory cell induce broad immunity antigen . In order examine issue , patient sarcomas , melanoma , germ cell tumor , epithelial malignancy metastatic lung , pleura mediastinum vaccinate irradiated K562 erythroleukemia cell express GM-CSF ( K562-GM ) follow thoracic metastasectomy . Vaccines administer conjunction metronomic oral cyclophosphamide ( 50 mg PO BID x 7d q 14d ) , celecoxib ( 400 mg PO BID ) . Serologic response variety recombinant CTAs assess vaccination . Primary Objectives : -To assess safety K562-GM allogeneic tumor cell vaccine combination oral metronomic cyclophosphamide celecoxib patient undergo thoracic metastasectomy . Eligibility : - Patients histologically cytologically proven sarcoma , melanoma , epithelial malignancy metastatic lung , pleura mediastinum render clinical evidence active disease ( NED ) . - Patients must 18 year old ECOG performance status 0 2 , without evidence unstable decompensated myocardial disease . Patients must adequate pulmonary reserve evidence FEV1 DLCO equal great 30 % predict ; pCO2 less 50 mm Hg pO2 great 60 mm Hg room air ABG ; immunosuppressive medication except inhaled corticosteroid time vaccination commences . - Patients must platelet count great 100,000 , ANC equal great 1500 without transfusion cytokine support , normal PT , adequate hepatic function evidence total bilirubin &lt; 1.5 time upper limit normal . Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) time vaccination commences . Design : - Following recovery thoracic metastasectomy , patient NED MRD vaccinate via deep subcutaneous injection 1x10 ( 8 ) irradiate K562 GM-tumor cell periodically 6 month . - Vaccines administer conjunction metronomic oral cyclophosphamide celecoxib . - Systemic toxicity , immunologic response therapy record . Pre post vaccination serologic responses standard panel CT antigens well cell mediate responses epigenetically-modified autologous EBV-transformed B autologous tumor cell ( available ) assess vaccination . - Numbers/percentages function T regulatory cell peripheral blood assess , , vaccination . - Patients follow clinic routine staging scan disease recurrence . - As exact set comparison analysis perform determine follow completion trial , base limited number patient , analysis consider exploratory hypothesis generate rather definitive . - Approximately 25 patient accrue trial .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients sarcomas , melanoma , germ cell tumor , epithelial malignancy metastatic lung , mediastinum , pleura clinical evidence active disease ( NED ) . 2 . Patients active disease outside thorax may eligible study extrathoracic disease definitively treat local modality radiation , surgery , radiofrequency ablation . 3 . Patients must receive refuse first line standard systemic therapy metastasis ( applicable ) . 4 . Patients must enrol within 52 week follow completion metastasectomy show evidence disease time . 5 . Patients intracranial metastasis , treat surgery radiation therapy may eligible study provide evidence active disease requirement anticonvulsant therapy steroid follow treatment . 6 . Patients must ECOG performance status 0 2 . 7 . Patients must 18 year age old due unknown effect immunologic response germ cellrestricted gene product childhood adolescent development . 8 . Patients must evidence adequate bone marrow reserve , hepatic renal function evidence follow laboratory parameter : Absolute neutrophil count great 1500/mm ( 3 ) Platelet count great 100,000/mm ( 3 ) Hemoglobin great 8g/dl ( patient may receive transfusion meet parameter ) PT within 2 second ULN Total bilirubin &lt; 1.5 time upper limit normal Serum creatinine less equal 1.6 mg/ml creatinine clearance must great 70 ml/min/1.73m ( 2 ) . 9 . Seronegative HIV antibody . Note : The experimental treatment evaluate protocol depend intact immune system . Patients HIV seropositive decrease immune competence thus may less responsive experimental treatment . 10 . Seronegative active hepatitis B , seronegative hepatitis C antibody . If hepatitis C antibody test positive , patient must test presence antigen RTPCR HCV RNA negative . 11 . Patients must aware neoplastic nature illness , experimental nature therapy , alternative treatment , potential benefit , risk . 12 . Patients must willing practice birth control four month follow treatment . 13 . Patients must willing sign inform consent . EXCLUSION CRITERIA : 1 . Patients initially render NED surgical therapy exhibit disease progression prior initiation vaccination exclude study . 2 . Patients require corticosteroid ( inhale ) exclude . 3 . Patients life expectancy le 12 month exclude . 4 . Patients receive warfarin anticoagulation , transfer agent enoxaparin dabigatran , anticoagulant hold 24 hour exclude . 5 . Patients uncontrolled hypertension ( &gt; 160/95 ) , unstable coronary disease evidence uncontrolled arrhythmia , unstable angina , decompensated CHF ( &gt; NYHA Class II ) , myocardial infarction within 6 month study exclude . 6 . Patients cardiac disease may exclude discretion PI follow consultation Cardiology consultant . 7 . Patients follow pulmonary function abnormality exclude : FEV , &lt; 30 % predict ; DLCO &lt; 30 % predict ( postbronchodilator ) ; Oxygen Saturation less 90 % room air . 8 . Pregnant and/or lactate woman exclude due unknown , potentially harmful effect immune response CTX antigens stem cell protein may express placenta , fetus , neonate . 9 . Patients active infection , include HIV , exclude , due unknown effect vaccine lymphoid precursor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 28, 2016</verification_date>
	<keyword>Metastatic Cancer</keyword>
	<keyword>Cancer Vaccine</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Adjuvant Therapy</keyword>
	<keyword>Chest Metastases</keyword>
	<keyword>Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Sarcoma</keyword>
</DOC>